BioStem Technologies R&D Spending Growth & History (BSEM)
BioStem Technologies's r&d spending was $7.1M for fiscal 2025.
View full BioStem Technologies company overviewBioStem Technologies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.1M | $5.2M | +270.80% |
| 2024 | 2024-12-31 | $1.9M | $1.6M | +458.79% |
| 2023 | 2023-12-31 | $341,996 | $117,221 | +52.15% |
| 2022 | 2022-12-31 | $224,775 | $105,128 | +87.87% |
| 2021 | 2021-12-31 | $119,647 | — | — |
BioStem Technologies quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $733,616 | −$1.2M | −62.52% |
| Q1 2026 | 2026-03-31 | $42 | $42 | — |
| Q3 2025 | 2025-09-30 | $2.0M | — | — |
| Q2 2025 | 2025-06-30 | $2.0M | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | $1.3M | — | — |
BioStem Technologies r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, BioStem Technologies's r&d spending increased from $119,647 to $7.1M, a change of $7.0M. The latest reported quarter, Q2 2026, shows $733,616.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioStem Technologies source filings ↗